Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2014


#198012

71pages

Global Markets Direct

$ 2000

In Stock

 

This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects.

 

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

  • The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

 

Reasons to buy

 

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents


Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview 8
Therapeutics Development 9
Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Overview 9
Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis 10
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Development by Companies 11
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Development by Companies 16
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Companies Involved in Therapeutics Development 17
Bioniche Life Sciences, Inc. 17
TARIS BioMedical, Inc. 18
Spectrum Pharmaceuticals, Inc. 19
Altor BioScience Corporation 20
Telormedix SA 21
Heat Biologics, Inc. 22
Viventia Biotechnologies Inc. 23
Cold Genesys, Inc. 24
Laurantis Pharma Oy 25
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 30
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
EN-3348 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
apaziquone - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CG-0070 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ALT-801 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
oportuzumab monatox - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
rAd-IFN - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
imiquimod - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ProtoCure Emulsion Cream - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
HS-410 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
APL-1202 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
TD-210 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
NMIBC Program - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DAB-389-EGF - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Recent Pipeline Updates 59
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects 66
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products 67
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Product Development Milestones 68
Featured News & Press Releases 68
Nov 05, 2012: Bioniche Life Sciences Discontinues Phase III Clinical Trial Of Urocidin 68
Apr 05, 2012: Spectrum Announces Results Of Apaziquone Phase III Clinical Trials 68
Mar 19, 2012: Telormedixs TMX-101 Exhibits High Safety In Phase I/II Trial For Non-Muscle Invasive Bladder Cancer 69
Jan 19, 2012: OncoGenex To Present OGX-427 Data At ASCO 2012 Genitourinary Cancers Symposium 69


Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 71
Disclaimer 71


Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H1 2014 9
Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Bioniche Life Sciences, Inc., H1 2014 17
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by TARIS BioMedical, Inc., H1 2014 18
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 19
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Altor BioScience Corporation, H1 2014 20
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Telormedix SA, H1 2014 21
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Heat Biologics, Inc.., H1 2014 22
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viventia Biotechnologies Inc., H1 2014 23
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Cold Genesys, Inc., H1 2014 24
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Laurantis Pharma Oy., H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Stage and Target, H1 2014 29
Number of Products by Stage and Mechanism of Action, H1 2014 32
Number of Products by Stage and Route of Administration, H1 2014 34
Number of Products by Stage and Molecule Type, H1 2014 36
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics - Recent Pipeline Updates, H1 2014 59
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects, H1 2014 66
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products, H1 2014 67


Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H1 2014 9
Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 27
Number of Products by Stage and Top 10 Target, H1 2014 28
Number of Products by Top 10 Mechanism of Action, H1 2014 30
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 31
Number of Products by Top 10 Route of Administration, H1 2014 33
Number of Products by Stage and Top 10 Route of Administration, H1 2014 34
Number of Products by Top 10 Molecule Type, H1 2014 35
Number of Products by Stage and Top 10 Molecule Type, H1 2014 36